StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Buy"

StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) from a hold rating to a buy rating in a research note published on Thursday morning.

Several other brokerages have also issued reports on ESPR. HC Wainwright reissued a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Wednesday, October 2nd. Needham & Company LLC dropped their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $8.17.

Esperion Therapeutics Trading Down 4.5 %

NASDAQ ESPR traded down $0.10 on Thursday, hitting $2.11. 11,838,630 shares of the company were exchanged, compared to its average volume of 6,152,476. The company has a market cap of $414.05 million, a PE ratio of -2.45 and a beta of 0.96. Esperion Therapeutics has a 12 month low of $0.87 and a 12 month high of $3.40. The stock has a fifty day moving average of $1.91 and a 200-day moving average of $2.13.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.10. The company had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million. On average, analysts expect that Esperion Therapeutics will post -0.09 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ESPR. BOKF NA purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at about $26,000. Traphagen Investment Advisors LLC purchased a new stake in shares of Esperion Therapeutics in the third quarter valued at about $27,000. Xponance Inc. purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at about $28,000. CVI Holdings LLC purchased a new stake in shares of Esperion Therapeutics in the first quarter valued at about $37,000. Finally, Sivia Capital Partners LLC purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at about $44,000. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.